Dazukibart

Summary

Dazukibart (CHEMBL4297808) is a phase-3 clinical-stage antibody; indicated across 4 conditions including myositis disease and dermatomyositis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 4 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297808
Name	Dazukibart
Type	Antibody
Max phase	3

Also known as: Dazukibart, Pf-06823859, PF-06823859, PF06823859, DAZUKIBART

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
myositis disease	3	MONDO:0021167	EFO:0000783
dermatomyositis	2	MONDO:0016367	EFO:0000398
cutaneous lupus erythematosus	2	MONDO:0005282	EFO:0003834
systemic lupus erythematosus	2	MONDO:0007915	MONDO:0007915

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05895786	PHASE3	RECRUITING	A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
NCT06698796	PHASE3	RECRUITING	A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
NCT03181893	PHASE2	COMPLETED	A Study In Adults With Moderate To Severe Dermatomyositis
NCT05879718	PHASE2	TERMINATED	A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.
NCT02766621	PHASE1	COMPLETED	Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859
NCT05037409	PHASE1	COMPLETED	Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).